Stivarga (regorafenib) — United Healthcare

Initial criteria

• Diagnosis of one of the following bone cancers: Dedifferentiated chondrosarcoma OR Ewing Sarcoma OR High grade undifferentiated pleomorphic sarcoma (UPS) OR Mesenchymal chondrosarcoma OR Osteosarcoma OR Other primary round cell tumors of the bone (e.g., CIC::DUX4, BCOR::CCNB3)
• Used as second-line therapy

Reauthorization criteria

• Patient does not show evidence of progressive disease while on Stivarga therapy

Approval duration

12 months